R. Stone

The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia

Karl W. Kroll, C. Bloomfield, J. Byrd, 2017, Leukemia.

Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a pros

W. Hiddemann, M. Qumsiyeh, H. Einsele, 2006, Blood.

Pharmacokinetics (PK) and pharmacodynamics (PD) of midostaurin (PKC412) in patients with acute myeloid leukemia (AML)

H. Schran, O. Yin, Yanfeng Wang, 2008 .